← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
101	101 CAMP4 Therapeutics CAMP $216M	–	–	–	–
102	102 Celularity CELU $42.5M	–	–	–	–
103	103 Creative Medical Technology CELZ $6.04M	–	–	–	–
104	104 DELISTED CERo Therapeutics CERO	–	–	–	–
105	105 Calidi Biotherapeutics CLDI $2.25M	–	–	–	–
106	106 DELISTED Centogene N.V. Common Shares CNTG	–	–	–	–
107	107 Coya Therapeutics COYA $103M	–	–	–	–
108	108 Caribou Biosciences CRBU $48.6M	–	–	–	–
109	109 DELISTED CARGO Therapeutics CRGX	–	–	–	–
110	DBTX 110 DELISTED Decibel Therapeutics, Inc. Common Stock DBTX	–	–	–	–
111	111 Ginkgo Bioworks DNA $774M	–	–	–	–
112	112 Design Therapeutics DSGN $650M	–	–	–	–
113	113 Precision BioSciences DTIL $169M	–	–	–	–
114	114 enGene Therapeutics ENGN $112M	–	–	–	–
115	115 Estrella Immunopharma ESLA $19.4M	–	–	–	–
116	116 FibroBiologics FBLG $7.07M	–	–	–	–
117	117 4D Molecular Therapeutics FDMT $707M	–	–	–	–
118	FRLN 118 DELISTED Freeline Therapeutics Holdings plc American Depositary Shares FRLN	–	–	–	–
119	119 DELISTED Generation Bio GBIO	–	–	–	–
120	120 CytoMed Therapeutics GDTC $10M	–	–	–	–
121	121 Guardant Health GH $22.4B	–	–	–	–
122	GMDA 122 DELISTED Gamida Cell Ltd. Ordinary Shares GMDA	–	–	–	–
123	123 Corgi Genomics & Precision Medicine ETF GNMX $1.67M	–	–	–	–
124	124 Global X Genomics & Biotechnology ETF GNOM $99.3M	–	–	–	–
125	125 Genprex GNPX $1.93M	–	–	–	–